Detalhe da pesquisa
1.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Hematol Oncol
; 42(3): e3274, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711253
2.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
3.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
4.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Am J Hematol
; 98(2): 272-281, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309981
5.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol
; 40(2): 269-279, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35043428
6.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Jpn J Clin Oncol
; 52(1): 29-38, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739075
7.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood
; 134(2): 111-122, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023700
8.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Blood
; 133(1): 7-17, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361262
9.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Am J Hematol
; 96(2): 208-217, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119898
10.
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Jpn J Clin Oncol
; 51(6): 857-864, 2021 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712849
11.
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood
; 131(15): 1704-1711, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29305552
12.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica
; 104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923097
13.
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Hematol Oncol
; 37(4): 464-473, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31251400
14.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(1): 65-75, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29246803
15.
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 19(2): 216-228, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339097
16.
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Oncologist
; 22(11): 1283-1291, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28851760
17.
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Am J Hematol
; 97(11): E422-E425, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053878
18.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Am J Hematol
; 97(11): E416-E419, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054316
19.
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): E299-E303, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567776
20.
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Br J Haematol
; 185(5): 961-966, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478940